SG11201804578PA - Oligonucleotides in food, beverage, cosmetic and medicinal formulations - Google Patents

Oligonucleotides in food, beverage, cosmetic and medicinal formulations

Info

Publication number
SG11201804578PA
SG11201804578PA SG11201804578PA SG11201804578PA SG11201804578PA SG 11201804578P A SG11201804578P A SG 11201804578PA SG 11201804578P A SG11201804578P A SG 11201804578PA SG 11201804578P A SG11201804578P A SG 11201804578PA SG 11201804578P A SG11201804578P A SG 11201804578PA
Authority
SG
Singapore
Prior art keywords
international
food
formulations
oligonucleotides
cosmetic
Prior art date
Application number
SG11201804578PA
Inventor
Johannes Kabisch
Gunter Festel
Original Assignee
Dna Essence Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dna Essence Gmbh filed Critical Dna Essence Gmbh
Publication of SG11201804578PA publication Critical patent/SG11201804578PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • A61K8/606Nucleosides; Nucleotides; Nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/005Preparations for sensitive skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Birds (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau ires.. 00) (43) International Publication Date ..... ..sr ,„,„.1 8 June 2017 (08.06.2017) W I P0 1 PCT (10) WO International 111111111111311111111111111111111111111111111111111111111111111111111311111111111111111 2017/092808 Publication Al Number (51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 8/60 (2006.01) A61Q 19/00 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (21) International Application Number: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PCT/EP2015/078484 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (22) International Filing Date: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 3 December 2015 (03.12.2015) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (8 4 ) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: DNA ESSENCE GMBH [CH/CH]; Mettlen- TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, strasse 14, 6363 Filrigen (CH). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors: KABISCH, Johannes; Am St. Georgsfeld 48, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 17489 Greifswald (DE). FESTEL, Gunter; Mettlenstrasse SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, 14, 6363 Filrigen (CH). GW, KM, ML, MR, NE, SN, TD, TG). (74) Agent: Stolmar & Partner; Blumenstrasse 17, 80331 Published: Miinchen (DE). — with international search report (Art 21(3)) (81) Designated States (unless otherwise indicated, for every with amended claims (Art 19(1)) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, — with sequence listing part of description (Rule 5.2(a)) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (54) Title: OLIGONUCLEOTIDES IN FOOD, BEVERAGE, COSMETIC AND MEDICINAL FORMULATIONS (57) : The present invention relates to foiinulations comprising oli- Fig. 1 gonucleotides of mammalian, avian, reptilian or plant, non-human DNA. The formulations may be food, beverage food, cosmetic or medicinal formu- 2 8 S 0 lations. In one aspect, the oligonucleotides are present in the form of DNA- carrier complexes. Further provided are a kit comprising a foiinulation ac - = Blank i invention for foiinulations cording to the and a method producing the of the , , invention. It is also envisaged that the formulations are used in personal lub - ricants or spice mixtures. stabil H , Stabi2 i 0 il Stabl3 - I , ILF adl No Stflbi i Stabil - Stabt2 - ' L 1 N 4 . sth— 1 HI a Stabt4 - t °' No Stahl - I MP — Il Stahil ' 1 ' f j w GC rt Stabi3 - 01 0 Stabi4 - o i Na Stab! - t ' ° ei cn GC C t--- 1-1 C ei O
SG11201804578PA 2015-12-03 2015-12-03 Oligonucleotides in food, beverage, cosmetic and medicinal formulations SG11201804578PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2015/078484 WO2017092808A1 (en) 2015-12-03 2015-12-03 Oligonucleotides in food, beverage, cosmetic and medicinal formulations

Publications (1)

Publication Number Publication Date
SG11201804578PA true SG11201804578PA (en) 2018-06-28

Family

ID=54838323

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201804578PA SG11201804578PA (en) 2015-12-03 2015-12-03 Oligonucleotides in food, beverage, cosmetic and medicinal formulations

Country Status (6)

Country Link
US (1) US20200230166A1 (en)
EP (1) EP3383361B1 (en)
JP (1) JP2019501961A (en)
CN (1) CN108778236A (en)
SG (1) SG11201804578PA (en)
WO (1) WO2017092808A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
CN1490056A (en) * 2002-10-18 2004-04-21 ��¡���ɵ°��̲��о����� Immune method and composition for HIV-1
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
MX354555B (en) * 2009-06-08 2018-03-09 Amunix Operating Inc Growth hormone polypeptides and methods of making and using same.
CN103687957A (en) * 2011-05-17 2014-03-26 现代治疗公司 Engineered nucleic acids and methods of use thereof for non-human vertebrates
MX358706B (en) * 2012-03-27 2018-08-31 Curevac Ag Artificial nucleic acid molecules comprising a 5'top utr.

Also Published As

Publication number Publication date
WO2017092808A1 (en) 2017-06-08
CN108778236A (en) 2018-11-09
EP3383361B1 (en) 2021-08-11
EP3383361A1 (en) 2018-10-10
JP2019501961A (en) 2019-01-24
US20200230166A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201810117WA (en) Human platelet lysate derived extracellular vesicles for use in medicine
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201811432WA (en) Rna for cancer therapy
SG11201807573VA (en) Methods for providing single-stranded rna
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201804398XA (en) Method for producing rna molecule compositions
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201808108XA (en) Synthesis of indazoles
SG11201901494UA (en) Acid-alpha glucosidase variants and uses thereof
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201808686VA (en) Synthesis of indazoles
SG11201805001UA (en) Method of treating influenza a
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof